Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) (“Ecopetrol” or the “Company”) announces that, The Chief Executive Officer of Ecopetrol S.A. (“Ecopetrol”) hereby summons all Shareholders to the extraordinary Assembly of the General Shareholders' Meeting to be held on Tuesday, November 11th, 2025, starting at 8:00 a.m., at the Auditorium of the Centro Internacional de Negocios y […]
Advancing Combinatorial Anti-Aging Therapies SINGAPORE, SG / ACCESS Newswire / October 22, 2025 / Immortal Dragons, a $40 million longevity fund, announced its strategic investment in Unlimited Bio, a biotechnology company developing combinatorial therapies to address the multi-system nature of aging. Combinatorial Therapeutic Strategy Unlimited Bio’s platform integrates gene therapies, biologics, plasma-based interventions, cell therapies,
Philadelphia, PA, Oct. 22, 2025 (GLOBE NEWSWIRE) — The Option Sellers School (OSS), founded by seasoned options trader and educator Peter Pru, has just launched and it's quickly gaining traction among everyday investors seeking a simpler, more transparent path to income generation. The platform's flagship curriculum, the Ark Options Strategy, draws on more than a
NEW YORK, NY / ACCESS Newswire / October 22, 2025 / If you suffered a loss on your Baxter International, Inc. (NYSE:BAX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=173518&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
Peter Pru Launches Option Sellers School and the Ark Options Strategy to Redefine Options Education for Everyday Investors A transparent, education-first approach helping busy professionals generate consistent income without day trading. GlobeNewswire October 23, 2025 Philadelphia, PA, Oct. 22, 2025 (GLOBE NEWSWIRE) — The Option Sellers School (OSS), founded by seasoned options trader and educator
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting inflammatory diseases today announced that Dr. André Boulet, PhD, Chairman and Chief Executive Officer, will present at
HarbourBioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced positive Phase II clinical data for porustobart (HBM4003), a next-generation, fully human heavy-chain-only anti-CTLA-4 antibody, in combination with tislelizumab, in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC). https://mma.prnewswire.com/media/1096360/HB_for_email_Logo.jpg The multicenter,
NEW YORK, NY / ACCESS Newswire / October 22, 2025 / If you suffered a loss on your investment in Savara Inc. ("Savara" or the "Company") (NASDAQ:SVRA), contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities
(NASDAQ:HCM),(LSE – AIM:HCM),(HKSE:0013), — First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities — — Unique, highly potent PI3K/PIKK inhibitor payload optimized to exploit antibody-conjugate advantages, with directed delivery and low plasma exposure of free payload — — Preclinical data shows robust antitumor activity
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire October 23, 2025 — First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities — — Unique, highly potent PI3K/PIKK inhibitor payload optimized to exploit antibody-conjugate advantages, with